Researchers in Canada, have reported the first quantitative choroidal assessment in a cohort of patients with genetically characterized retinitis pigmentosa (RP). The results of the… Read More »First quantitative choroidal assessment may be valuable for using other standard metrics for retinal clinical trial evaluations.
Atsena Therapeutics, based in Durham, North Carolina, has announced that the U.S. Food and Drug Administration (FDA) has agreed to the expansion of the company’s… Read More »Astena Therapeutics has announced an expansion of a Phase 1 / 2 study into a continuous Phase 1 / 2 / 3 trial, agreed by U.S. Food and Drug Administration (FDA).
Dear EURETINA Members, A very warm welcome to the July 7th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »July 7th, 2025 “EURETINA-Brief”© Issue No. 320
Researchers based in the Institute of Ophthalmology, University College London, and Moorfields Eye Hospital, London, UK have presented a deep learning model – “Eye2gene” –… Read More »Eye2Gene performance of genetic diagnosis showed better results from any single human ophthalmic expert.
Economic estimates have indicated that 2.25 billion coffees are consumed every day – this is a significant number. Researchers at the Department of Ophthalmology, Hubei… Read More »Anyone for a coffee – instant coffee may increase the risk of AMD, and reducing instant coffee intake can prevent dry AMD.
Clinical trial research on the treatment of sub-cutaneous (subQ) migaldendranib (MGB), sponsored by Ashvattha Therapeutics, has announced interim results from an ongoing Phase II study… Read More »Potential paradigm shift of anti-VEGF treatment with sub-cutaneous injections at home, following Phase II summary results.
Dear EURETINA Members, A very warm welcome to the June 23rd, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »June 23rd, 2025 “EURETINA-Brief”© Issue No. 319
Researchers based in Moorfields Eye Hospital, NHS Foundation Trust, London, have presented the first genome-wide association study (GWAS) results involving reticular pseudodrusen (RPD). The study’s… Read More »First genome-wide association study (GWAS) on reticular pseudodrusen (RPD) provides a clear relationship between RPD and the ARMS2-HTRA1 locus.
An independent study, funded by the Swedish government, has reported that intravitreal injections of anti-VEGF treatments were associated with a 2.9% risk for stroke among… Read More »Swedish clinical study reports a 3% increased risk of stroke within 90 days of anti-VEGF treatments.
VeonGen Therapeutics GmbH, based in Munich, Germany, have announced the progression of two proprietary gene therapies to the clinic based on a novel gene therapy… Read More »VeonGen Therapeutics GmbH announce re-branding of the company (previously ViGeneron) and the progression of treatments for Stargardt’s disease and retinitis pigmentosa.
